Cargando…
Tegafur/gimeracil/oteracil‐induced eosinophilic pneumonia
Clinicians should be aware that eosinophilic pneumonia is one of the types of drug‐induced lung injury that can be caused by tegafur/gimeracil/oteracil (TS‐1).
Autores principales: | Sumi, Toshiyuki, Nakata, Hisashi, Mori, Yuji, Takahashi, Hiroki |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons, Ltd
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7063347/ https://www.ncbi.nlm.nih.gov/pubmed/32180985 http://dx.doi.org/10.1002/rcr2.551 |
Ejemplares similares
-
Activity and Safety of Tegafur, Gimeracil, and Oteracil Potassium for Nasopharyngeal Carcinoma: A Systematic Review and Meta-Analysis
por: Zhang, Ximing, et al.
Publicado: (2021) -
Successful management of therapy‐related chronic myelomonocytic leukemia with cytarabine, aclarubicin, and azacitidine following tegafur/gimeracil/oteracil
por: Nakako, Soichiro, et al.
Publicado: (2021) -
Short-term clinical effect of conformal radiotherapy combined with tegafur gimeracil oteracil potassium in treating recurrent esophagus cancer
por: Jiao, Yuyan, et al.
Publicado: (2016) -
Safety of alternate-day treatment with TS-1(TM)
(tegafur/gimeracil/oteracil) in tumor-bearing dogs: a pilot study
por: NISHIYAMA, Yuta, et al.
Publicado: (2021) -
A fatal myelosuppression, diarrhea and neurotoxicity induced by combination of irinotecan and tegafur-gimeracil-oteracil potassium in the treatment of colon cancer: a case report
por: Liu, Yang-Xi, et al.
Publicado: (2020)